About: Inhibition of Bruton tyrosine kinase in patients with severe COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Inhibition of Bruton tyrosine kinase in patients with severe COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
Creator	Chung, Kevin Rose, Keith Lionakis, Michail Roshon, Michael Wright, George Baselga, Jose Collen, Jacob Desai, Jigar Goy, Andre Hamdy, Ahmed Izumi, Raquel Monticelli, M Roswarski, Joseph Roschewski, Mark Sharman, Jeff Staudt, Louis Wilson, Wyndham Wrzesinski, Stephen Zarakas, Marissa
Source	Medline; PMC
abstract	Patients with severe COVID-19 have a hyperinflammatory immune response suggestive of macrophage activation. Bruton tyrosine kinase (BTK) regulates macrophage signaling and activation. Acalabrutinib, a selective BTK inhibitor, was administered off-label to 19 patients hospitalized with severe COVID-19 (11 on supplemental oxygen; 8 on mechanical ventilation), 18 of whom had increasing oxygen requirements at baseline. Over a 10-14 day treatment course, acalabrutinib improved oxygenation in a majority of patients, often within 1-3 days, and had no discernable toxicity. Measures of inflammation – C-reactive protein and IL-6 – normalized quickly in most patients, as did lymphopenia, in correlation with improved oxygenation. At the end of acalabrutinib treatment, 8/11 (72.7%) patients in the supplemental oxygen cohort had been discharged on room air, and 4/8 (50%) patients in the mechanical ventilation cohort had been successfully extubated, with 2/8 (25%) discharged on room air. Ex vivo analysis revealed significantly elevated BTK activity, as evidenced by autophosphorylation, and increased IL-6 production in blood monocytes from patients with severe COVID-19 compared with blood monocytes from healthy volunteers. These results suggest that targeting excessive host inflammation with a BTK inhibitor is a therapeutic strategy in severe COVID-19 and has led to a confirmatory international prospective randomized controlled clinical trial.
has issue date	2020-06-05(xsd:dateTime)
bibo:doi	10.1126/sciimmunol.abd0110
bibo:pmid	32503877
has license	cc-by
sha1sum (hex)	fb88204ac6b686beac83a60be7ac98a9452705d6
schema:url	https://doi.org/10.1126/sciimmunol.abd0110
resource representing a document's title	Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
has PubMed Central identifier	PMC7274761
has PubMed identifier	32503877
schema:publication	Sci Immunol
resource representing a document's body	covid:fb88204ac6b686beac83a60be7ac98a9452705d6#body_text
is schema:about of	named entity 'acalabrutinib' named entity 'off-label' named entity '37°C' named entity '3G8' named entity 'inflammation' named entity 'COVID-19' named entity 'complete blood counts' named entity 'MCP-1' named entity 'COVID-19' named entity 'COVID-19' named entity 'IL-6' named entity 'set point' named entity 'monocytes' named entity 'clone' named entity 'supplemental oxygen' named entity 'COVID' named entity 'CD14' named entity 'clone' named entity 'acalabrutinib' named entity 'Thermo Fisher' named entity 'COVID-19' named entity 'data analysis' named entity 'COVID' named entity 'Laboratory tests' named entity 'homeostasis' named entity 'supplemental oxygen' named entity 'IgG' named entity 'malabsorption syndromes' named entity 'cytokine' named entity 'monocytes' named entity 'mechanical ventilation' named entity 'informed consent' named entity 'sequelae' named entity 'CRP' named entity 'acalabrutinib' named entity 'monocytes' named entity 'oxygen' named entity 'acalabrutinib' named entity 'virally' named entity 'COVID-19' named entity 'polystyrene' named entity 'COVID' named entity 'COVID' named entity 'CRP' named entity 'ibrutinib' named entity 'monocytes' named entity 'organ dysfunction' named entity 'IL-6' named entity 'phosphorylation' named entity 'non-specific' named entity 'Flow cytometric analysis' named entity 'protein' named entity 'innate immune cells' named entity 'off-label' named entity 'mechanical ventilation' named entity 'inhaled steroids' named entity 'inflammation' named entity 'method of administration' named entity 'phosphorylated' named entity 'monocytes' named entity 'intubation' named entity 'covalent' named entity 'IL-6'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software